TMCnet News
Next-Generation Sequencing: Emerging Clinical Applications and Global MarketsLONDON, Sept. 9, 2015 /PRNewswire/ -- This BCC Research report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. Market data covers the years 2014, 2015 and 2020. Beginning in 2005, the launch of next-generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is beginning to establish a foothold in the molecular diagnostic industry and holds great commercial promise. More than 85 clinical laboratories are now offering NGS-based testing services. For many applications, the clinical benefits have been proven. At the same time, payers and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential. The outstanding growth potential for NGS diagnostics makes it particularly timely to update an earlier report, published in 2013. CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE This report fills a gap in the industry by focusing solely on clinical applications run on next-generation sequencing instruments. Because this industry shows great promise, information about the market will be particularly useful to companies and other institutions. The report provides a roadmap for understanding the ways in which next-generation sequencing will be used in the diagnostic business during the next five years. It is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in clinical diagnostics. This market report will be useful to many companies involved in the clinical, genetic testing and sequencing industries. It will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip and sample preparation. SCOPE AND FORMAT The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2014, 2015 and 2020. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed. The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future. The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, complex disorders and reproductive health. Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world. Market data covers the years 2014, 2015 and 2020. Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratory testing services, reproductive health diagnostics, HLA typing, liquid biopsy, immune sequencing and fusion diagnostics. More than 170 companies in the clinical NGS industry are profiled in this report. BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2013 through 2015, including key alliance trends. METHODOLOGY Both primary and secondary research methodologies were used in preparing this study. BCC Research examined each of the key end-user market segments that will be commercially important during the next five years: cancer, rare genetic disorders, complex disorders and reproductive health. Based on this analysis, the current and future applications of NGS technologies are evaluated in each of the major clinical market segments and sales revenues are forecast for 2015 through 2020. Based on analysis of both secondary and primary market sources, as well as the key trends in the industry, the report provides the current and projected market size for the various clinical NGS segments for the years 2014, 2015 and 2020. Download the full report: https://www.reportbuyer.com/product/1556799/ To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/next-generation-sequencing-emerging-clinical-applications-and-global-markets-300140496.html SOURCE ReportBuyer |